BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16386620)

  • 1. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
    Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
    Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with daclizumab in heart transplantation--how many doses?
    Ortiz V; Almenar L; Martínez-Dolz L; Zorio E; Chamorro C; Moro J; Agüero J; Rueda J; Arnau MA; Salvador A
    Transplant Proc; 2006 Oct; 38(8):2541-3. PubMed ID: 17097995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
    Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
    N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
    Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
    Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ; Alloway RR; Lo A; Hodge E
    Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
    Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH
    Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1080-1. PubMed ID: 15194375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D; Cantarovich M; Cecere R; Giannetti N
    Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
    Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
    J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
    Campos A; Lage E; Hinojosa R; Ordóñez A; Cisneros JM; Cabezón S; Gómez S; Aguilera A; Arana E; Cayuela A
    Transplant Proc; 2005 Apr; 37(3):1548-9. PubMed ID: 15866669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression induction with daclizumab and antithymocyte globulin in cardiac transplantation: clinical experience with 8 cases.
    Huang XS; Chen DZ; Chen LW; Li ZQ; Liao CX
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):126-8. PubMed ID: 14965807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
    Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
    Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
    Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
    Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation.
    Alonso-Pulpón L; Serrano-Fiz S; Rubio JA; Cavero MA; Silva L; Sánchez-Vegazo I; Burgos R; Montero CG; Maicas C; Kreisler M
    J Heart Lung Transplant; 1995; 14(1 Pt 1):136-42. PubMed ID: 7727462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.